Credit Agricole
VYGR icon

Credit Agricole’s Voyager Therapeutics VYGR Stock Holding History

Credit Agricole’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-45,700
Closed -$430K – 510
2018
Q4 		$430K Buy
45,700
+100
+0.2% +$1.28K 0.02% 334
2018
Q3 		$862K Buy
45,600
+11,000
+32% +$211K 0.04% 277
2018
Q2 		$676K Buy
+34,600
New +$684K 0.05% 252

Other funds holding VYGR

TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HCM
Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return

Credit Agricole's VYGR Position: Q1 2019 in Review

Credit Agricole sold out of Voyager Therapeutics (VYGR) in Q1 2019, closing a stake of 45,700 shares — an estimated $430K sold.

Credit Agricole first reported a position in VYGR in Q2 2018 and held it in 3 quarters. The position peaked at $862K in Q3 2018. 111 funds tracked by Wall St. Rank hold VYGR as of Q1 2019.

  • Credit Agricole reported no remaining Voyager Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Credit Agricole sold 45,700 Voyager Therapeutics shares in Q1 2019, an estimated $430K.
  • Credit Agricole first reported a position in Voyager Therapeutics in Q2 2018 and held it in 3 quarters.
  • Credit Agricole's Voyager Therapeutics position peaked at $862K in Q3 2018.
  • 111 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q1 2019.

Based on Credit Agricole's 13F filing for Q1 2019, filed 14 May 2019.